Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Should Reconsider Electroconvulsive Therapy CPT Code – HHS OIG

This article was originally published in The Gray Sheet

Executive Summary

The Centers for Medicare & Medicaid Services will evaluate the appropriateness of multiple-monitored electroconvulsive therapy in its April review of CPT codes, following a December 2001 recommendation by the HHS Office of the Inspector General

You may also be interested in...

Multiple monitored electroconvulsive therapy

CMS' Nov. 19 decision not to cover MMECT follows a 1December 2001 HHS Office of the Inspector General report which concluded that the procedure is being used too frequently (2"The Gray Sheet" Jan. 14, 2002, p. 32). The agency found that literature supporting the use of MMECT "reflected substantial methodological shortcomings." In addition, evidence concluded that MMECT may pose additional safety risks over conventional one-time ECT for patients with affective disorders or other psychiatric disorders without a balancing clinical benefit, the decision memorandum states. The agency says it is open to considering evidence for narrowly defined, non-routine uses of MMECT if it is brought to CMS' attention in the future; however, no comments from professional organizations or the general public were submitted during the course of the review...

Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab

China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts